Alvarez & Marsal Announces 2025 Managing Director Promotions
16.1.2025 17:36:00 CET | Business Wire | Press Release
Leading global professional services firm Alvarez & Marsal (A&M) has announced the promotion of 80 professionals, across Brazil, Canada, France, Germany, India, Italy, Spain, Sweden, United Arab Emirates, United Kingdom, and the United States, to the position of Managing Director.
Tony Alvarez II and Bryan Marsal, A&M’s Co-Founders, stated, “All of our newly promoted Managing Directors embody the talent and leadership necessary to deliver exceptional results that create value for A&M’s clients. Their contributions to the growth of our firm and the clients we serve cannot be understated. From around the world and across our many lines of service, they exemplify A&M’s unwavering commitment to integrity, quality and objectivity, and are essential to the firm’s continued success and expansion.”
- Russell Hunt, Houston
- Jack Kobus, Detroit
- Long Nguyen, Washington, D.C.
- Luis De Lencquesaing, New York
- Christopher Disa, New York
- Phani Mogalapu,Houston
Corporate Performance Improvement
- Kindra Bradshaw, Washington, D.C.
- Clark Caperton, Houston
- Rodrigo Carrillo, Houston
- Jeffrey Cass, Houston
- Trey Huffman, Atlanta
- Rob Koczo,Dallas
- Haley Leyendecker, Denver
- Andrew Monaco, Dallas
- Dan Phillips, Atlanta
- Brenden Phillips-Garrett, Los Angeles
- Eduardo Areilza, Madrid
- Massimo Franzese, London
- Tom Howitt, Abu Dhabi
- Hardeep Sandhu, London
- Florian Seehauser, Munich
- Jonas Strasdas, Munich
Private Equity Performance Improvement
- Colleen McCaughan, London
- Nick Mountfield, London
- Daniela Torresin, Milan
- Dario Bortot,London
- John Costoudes, Dubai
- Elizaveta Malashenko, Houston
Global Disputes and Investigations
- Jon Ahern, Denver
- Brad Koehler, New York
- John Bettley-Smith, London
- Daniella Divito,New York
- Emily Edwards, Atlanta
- Orion Ganase,London
- Alon Kritzman, New York
- Bruce Meyer, San Francisco
- Michael Noreman, Morristown
- Axel Ortjohann, Frankfurt
- Rob Piechota, Atlanta
- Chris Prout, London
Global Transaction Advisory Group
- Mike Baxter,Toronto
- Erminio Caporale, Chicago
- Kevin Cunha,San Francisco
- Ryan Donovan,Boston
- Vivian Leemans,Düsseldorf
- Kate Lowry,New York
- Ryan Macke, Chicago
- Callum Moore, Stockholm
- Gaurav Patel,Toronto
- Alex Rankin, Dubai
- Simon Regad,Paris
- Paul Spencer, London
- Michael Surr,New York
- Austin Wanland, Los Angeles
- Sujith Jain, Bangalore
Infrastructure & Capital Projects
- Felipe Bergson, Rio de Janeiro
- Bryan Müller, Belo Horizonte
- Alexandre Aguieiras, Rio de Janeiro
- Janice Garay, São Paulo
- Guilherme Kam, São Paulo
- Patrick Lopes, São Paulo
- Eduardo Teixeira, São Paulo
North American Commercial Restructuring
- Dwight Hingtgen,Chicago
- Landon Kenworthy,Dallas
- Paul Kinealy,Chicago
- Kumanan Ramanathan, New York
- Mauricio Rivera,San Francisco
- John Walsh,Houston
Private Equity Performance Improvement
- Alexander Galitsky,Chicago
- Vincent Juron,Charlotte
- Jason Kahn,Philadelphia
- Jeff Liddle, Houston
- Ahmed Suria,Philadelphia
- Ben Taylor,Atlanta
- Shiwali Tenner,Chicago
- Hameer Vaid,New York
- Christopher Baglio, Chicago
- Tracey Esposito, New York
- Roger Wilcock, London
About Alvarez & Marsal
Founded in 1983, Alvarez & Marsal is a leading global professional services firm. Renowned for its leadership, action and results, Alvarez & Marsal provides advisory, business performance improvement and turnaround management services, delivering practical solutions to address clients' unique challenges. With a world-wide network of experienced operators, world-class consultants, former regulators and industry authorities, Alvarez & Marsal helps corporates, boards, private equity firms, law firms and government agencies drive transformation, mitigate risk and unlock value at every stage of growth.
To learn more, visit: AlvarezandMarsal.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250114027719/en/
Contacts
Sandra Sokoloff, Senior Director of Global Public Relations
Alvarez & Marsal, +1 212-763-9853
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK ® and TRIKAFTA ® , Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 13:30:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported by clinical and/or in vitro data from 564 variants demonstrating response to ALYFTREK and 521 variants demonstrating response to TRIKAFTA. As such, approximately 800 more people with a clinical diagnosis of CF in the U.S. are now eligible for a medicine that treats the underlying cause of their disease for the first time. This extension means approxim
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 13:30:00 CEST | Press Release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooperative networks of CCTG, GI Cancer Trials in Australia and France’s Partenariat de Recherche en Oncologie Digestive (PRODIGE) consortium (including Unicancer, GERCOR and FFCD). The BATTMAN (CO.33) trial serves as the registrational-enablin
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 13:19:00 CEST | Press Release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press Release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 13:00:00 CEST | Press Release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom